Contagion Live: Targeting Lung Blood Vessel Inflammation in COVID-19 Patients
UC cardiologist discusses use of razuprotafib to lessen blood vessel inflammation
Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, was interviewed by a reporter for Contagion Live about a new phase 2 clinical trial UC and UC Health are conducting using the drug razuprotafib, to lessen inflammation of the blood vessels in COVID-19 patients. Razuprotafib activates a key pathway for stabilizing blood vessels in the lungs and may prevent or treat respiratory distress in COVID-19 patients. Becker, also a UC Health cardiologist, and Duncan Hite, a professor in the UC College of Medicine, and medical director of critical care at UC Health, are overseeing the trial using razuprotafib at UC. The drug is being used as a part of clinical trial in 20 sites across the nation.
Listen to the Contagion Live interview online.
Learn more about the research involving Dr. Becker and Dr. Hite.
Related Stories
Ticks that survive pesticides can withstand colder winters
July 17, 2026
Ticks that survive less-than-lethal doses of pesticide are able to withstand dangerous cold, which could help them expand their range farther north, according to researchers at the University of Cincinnati and the U.S. Department of Agriculture.
Why does it feel like so many Cincinnati restaurants close?
July 17, 2026
WLWT and the Cincinnati Enquirer cited UC research in reports on recent restaurant closures in the city.
UC has connection to city of legend behind 'Odyssey'
July 17, 2026
WVXU highlights a big connection between Cincinnati and director Christopher Nolan's new movie "The Odyssey." UC Classics Professor Carl Blegen led excavations at Troy in the 1930s. UC has a vast collection of photos and other records from the ambitious archaeological project.